A new independent 1575 page research with title ‘Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes and important players/vendors With n-number of tables and figures examining the Glioblastoma Multiforme , the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/841033-glioblastoma-multiforme-5
The latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.
Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.
The Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 106, 65, 1, 8, 155, 23 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 12, 14, 1, 36 and 11 molecules, respectively.
Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
– The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=841033
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies mentioned in the Report
AbbVie Inc ,Accurexa Inc ,Actuate Therapeutics Inc ,Aduro BioTech Inc ,Advantagene Inc ,Advenchen Laboratories LLC ,Affimed GmbH ,Agenus Inc ,Ambrx Inc ,Amgen Inc ,Ampio Pharmaceuticals Inc ,AngioChem Inc ,Apac Biotech Pvt Ltd ,apceth Biopharma GmbH ,APIM Therapeutics AS ,Apogenix AG ,Ariad Pharmaceuticals Inc ,Arog Pharmaceuticals Inc ,Astellas Pharma Inc ,AstraZeneca Plc ,Athenex Inc ,Basilea Pharmaceutica Ltd ,Batu Biologics Inc ,Bayer AG ,Beactica AB ,BeiGene Ltd ,Berg LLC ,Bexion Pharmaceuticals LLC ,BeyondSpring Pharmaceuticals Inc ,Bio-Path Holdings Inc ,Bioasis Technologies Inc ,BioCancell Ltd ,Biovista Inc ,Boehringer Ingelheim GmbH ,Boston Biomedical Inc ,Bristol-Myers Squibb Co ,Cantex Pharmaceuticals Inc ,Cavion LLC ,Celgene Corp ,Celldex Therapeutics Inc ,Cellmid Ltd ,Celsion Corp ,ChemoCentryx Inc ,Coherus BioSciences Inc ,Cortice Biosciences Inc ,Critical Outcome Technologies Inc ,Curtana Pharmaceuticals Inc ,Cynata Therapeutics Ltd ,CytoVac AS ,Daiichi Sankyo Co Ltd ,Deciphera Pharmaceuticals LLC ,DEKK-TEC Inc ,DelMar Pharmaceuticals Inc ,Diffusion Pharmaceuticals Inc ,Dr. Reddy’s Laboratories Ltd ,Ecrins Therapeutics SAS ,Eisai Co Ltd ,Eli Lilly and Co ,EnGeneIC Ltd ,Enterome Bioscience SA ,EntreChem SL ,ERC Belgium SA ,Erytech Pharma SA ,Evotec AG ,F-star Biotechnology Ltd ,F. Hoffmann-La Roche Ltd ,FirstString Research Inc ,Fujifilm Holdings Corporation ,Gene Techno Science Co Ltd ,Genentech Inc ,Genisphere LLC ,Genor BioPharma Co Ltd ,GlaxoSmithKline Plc ,GlioPharma ApS ,GtreeBNT Co Ltd ,GW Pharmaceuticals Plc ,Hamlet Pharma AB ,Hanmi Pharmaceuticals Co Ltd ,Humanigen Inc ,Hutchison MediPharma Ltd ,Immatics Biotechnologies GmbH ,Immune Pharmaceuticals Inc ,ImmunoCellular Therapeutics Ltd ,Immunomedics Inc ,Immunomet Therapeutics Inc ,Immunomic Therapeutics Inc ,Incyte Corp ,Infinity Pharmaceuticals Inc ,Innovation Pharmaceuticals Inc ,Inovio Pharmaceuticals Inc ,Inspyr Therapeutics Inc ,Insys Therapeutics Inc ,Iovance Biotherapeutics Inc ,Ipsen SA ,Janpix Inc ,Jiangsu Kanion Pharmaceutical Co Ltd ,Johnson & Johnson ,Juno Therapeutics Inc ,Kadmon Corp LLC ,Karyopharm Therapeutics Inc ,Kazia Therapeutics Ltd ,Kite Pharma Inc ,Komipharm International Co Ltd ,Kringle Pharma Inc ,Kyorin Pharmaceutical Co Ltd ,Les Laboratoires Servier SAS ,Lixte Biotechnology Holdings Inc ,Loxo Oncology Inc ,Mabion SA ,MacroGenics Inc ,Medesis Pharma SA ,Medicenna Therapeutics Corp ,MedImmune LLC ,Merck & Co Inc ,Merck KGaA ,Midatech Pharma Plc ,Millennium Pharmaceuticals Inc ,MimiVax LLC ,Molecular Templates Inc ,Moleculin Biotech Inc ,Mycenax Biotech Inc ,NanoCarrier Co Ltd ,Nanomerics Ltd ,Nektar Therapeutics ,Neonc Technologies Inc ,NewLink Genetics Corp ,Northwest Biotherapeutics Inc ,Novartis AG ,Noxopharm Ltd ,Noxxon Pharma AG ,Nuo Therapeutics Inc ,NuvOx Pharma LLC ,Omniox Inc ,Oncobiologics Inc ,Oncodesign SA ,Onconova Therapeutics Inc ,OncoResponse Inc ,Oncternal Therapeutics Inc ,Ono Pharmaceutical Co Ltd ,Orphit SAS ,Oryx GmbH & Co KG ,Ovensa Inc ,Peloton Therapeutics Inc ,Peptomyc SL ,Peregrine Pharmaceuticals Inc ,Pfizer Inc ,Pharma Mar SA ,PharmAbcine Inc ,PharmaCyte Biotech Inc ,Pharmicell Co Ltd ,Phoenix Biotechnology Inc ,PIQUR Therapeutics AG ,Plex Pharmaceuticals Inc ,Plexxikon Inc ,Prana Biotechnology Ltd ,PTC Therapeutics Inc ,Puma Biotechnology Inc ,Regulus Therapeutics Inc ,ReNeuron Group Plc ,Rgenix Inc ,Richter Gedeon Nyrt ,Sanofi ,Sapience Therapeutics Inc ,Scancell Holdings Plc ,Sellas Life Sciences Group Ltd ,Sigma-Tau SpA ,SignPath Pharma Inc ,Silenseed Ltd ,SOM Biotech SL ,Sorrento Therapeutics Inc ,StemGen SpA ,Stemline Therapeutics Inc ,Sumitomo Dainippon Pharma Co Ltd ,Sun Pharma Advanced Research Company Ltd ,Sunesis Pharmaceuticals Inc ,Susavion Biosciences Inc ,Symphogen A/S ,Synactix Pharmaceuticals Inc ,Systimmune Inc ,Terpenoid Therapeutics Inc ,Theralase Technologies Inc ,Therapeia GmbH & Co KG ,Tocagen Inc ,TRACON Pharmaceuticals Inc ,Transgene SA ,Trillium Therapeutics Inc ,TVAX Biomedical Inc ,Tyme Technologies Inc ,Upsher-Smith Laboratories Inc ,Vascular Biogenics Ltd ,Vault Pharma Inc ,Vaximm AG ,VBI Vaccines Inc ,VCN Biosciences SL ,ViraTherapeutics GmbH ,Vyriad Inc ,X4 Pharmaceuticals Inc ,Xintela AB ,Yooyoung Pharm Co Ltd ,ZIOPHARM Oncology Inc
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/841033-glioblastoma-multiforme-5
Table of Contents
Glioblastoma Multiforme (GBM) – Overview 10
Glioblastoma Multiforme (GBM) – Therapeutics Development 11
Glioblastoma Multiforme (GBM) – Therapeutics Assessment 59
Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development 86
Glioblastoma Multiforme (GBM) – Drug Profiles 174
Glioblastoma Multiforme (GBM) – Dormant Projects 1503
Glioblastoma Multiforme (GBM) – Discontinued Products 1515
Glioblastoma Multiforme (GBM) – Product Development Milestones 1517
Appendix 1531List of Tables
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/841033-glioblastoma-multiforme-5
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218